Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer

Yuh Min Chen, Reury Perng Perng, Jacqueline Whang-Peng, Hsiao Wei Wu, Wei Chun Lin, Chun Ming Tsai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of the present study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine, ifosfamide and cisplatin (GIP), administered every 3 weeks, in patients with inoperable non-small cell lung cancer (NSCLC). From October 1998 to July 1999, 18 previously untreated stages IIIb (4) and IV (14) patients were enrolled into the study. Gemcitabine and ifosfamide (with mesna as uroprotection) was administered on days 1 and 6, at a dose of 1000 and 1500 mg/m2, respectively; and cisplatin was given on day 1 at a dose of 60 mg/m2, every 3 weeks. All 18 patients were evaluable for response and toxicity profiles. One patient achieved a complete response, and 11 patients achieved a partial response, with an overall response rate of 66.7% (95% CI, 45-89%). The main toxicity was hematological, a NCI grade 3-4 neutropenia in 16 patients (88.9%) during the treatment course. Febrile neutropenia occurred in three patients (16.6%). Grade 3 anemia occurred in eight patients (44.4%) and grade 3-4 thrombocytopenia occurred in 11 patients (61.1%). Non-hematological toxicity was mild and tolerable. No toxic death occurred. The median survival was 12.7 months and 1 year survival was 58.4%. The GIP combination chemotherapy produced a high response rate in advanced NSCLC; however, there was a relatively high percentage of hematological toxicity that still could be tolerated. A randomized trial comparing GIP to a two-drug combination of gemcitabine and cisplatin is planned.

Original languageEnglish
Pages (from-to)199-202
Number of pages4
JournalLung Cancer
Volume30
Issue number3
DOIs
Publication statusPublished - Dec 1 2000
Externally publishedYes

Fingerprint

gemcitabine
Ifosfamide
Non-Small Cell Lung Carcinoma
Cisplatin
Combination Drug Therapy
Mesna
Febrile Neutropenia
Survival
Poisons
Drug Combinations
Neutropenia

Keywords

  • Chemotherapy
  • Cisplatin
  • Gemcitabine
  • Ifosfamide
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer. / Chen, Yuh Min; Perng, Reury Perng; Whang-Peng, Jacqueline; Wu, Hsiao Wei; Lin, Wei Chun; Tsai, Chun Ming.

In: Lung Cancer, Vol. 30, No. 3, 01.12.2000, p. 199-202.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Perng, Reury Perng ; Whang-Peng, Jacqueline ; Wu, Hsiao Wei ; Lin, Wei Chun ; Tsai, Chun Ming. / Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer. In: Lung Cancer. 2000 ; Vol. 30, No. 3. pp. 199-202.
@article{f34834f4089a4f5e8930874bc4288636,
title = "Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer",
abstract = "The aim of the present study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine, ifosfamide and cisplatin (GIP), administered every 3 weeks, in patients with inoperable non-small cell lung cancer (NSCLC). From October 1998 to July 1999, 18 previously untreated stages IIIb (4) and IV (14) patients were enrolled into the study. Gemcitabine and ifosfamide (with mesna as uroprotection) was administered on days 1 and 6, at a dose of 1000 and 1500 mg/m2, respectively; and cisplatin was given on day 1 at a dose of 60 mg/m2, every 3 weeks. All 18 patients were evaluable for response and toxicity profiles. One patient achieved a complete response, and 11 patients achieved a partial response, with an overall response rate of 66.7{\%} (95{\%} CI, 45-89{\%}). The main toxicity was hematological, a NCI grade 3-4 neutropenia in 16 patients (88.9{\%}) during the treatment course. Febrile neutropenia occurred in three patients (16.6{\%}). Grade 3 anemia occurred in eight patients (44.4{\%}) and grade 3-4 thrombocytopenia occurred in 11 patients (61.1{\%}). Non-hematological toxicity was mild and tolerable. No toxic death occurred. The median survival was 12.7 months and 1 year survival was 58.4{\%}. The GIP combination chemotherapy produced a high response rate in advanced NSCLC; however, there was a relatively high percentage of hematological toxicity that still could be tolerated. A randomized trial comparing GIP to a two-drug combination of gemcitabine and cisplatin is planned.",
keywords = "Chemotherapy, Cisplatin, Gemcitabine, Ifosfamide, Non-small cell lung cancer",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Jacqueline Whang-Peng and Wu, {Hsiao Wei} and Lin, {Wei Chun} and Tsai, {Chun Ming}",
year = "2000",
month = "12",
day = "1",
doi = "10.1016/S0169-5002(00)00139-2",
language = "English",
volume = "30",
pages = "199--202",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

AU - Wu, Hsiao Wei

AU - Lin, Wei Chun

AU - Tsai, Chun Ming

PY - 2000/12/1

Y1 - 2000/12/1

N2 - The aim of the present study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine, ifosfamide and cisplatin (GIP), administered every 3 weeks, in patients with inoperable non-small cell lung cancer (NSCLC). From October 1998 to July 1999, 18 previously untreated stages IIIb (4) and IV (14) patients were enrolled into the study. Gemcitabine and ifosfamide (with mesna as uroprotection) was administered on days 1 and 6, at a dose of 1000 and 1500 mg/m2, respectively; and cisplatin was given on day 1 at a dose of 60 mg/m2, every 3 weeks. All 18 patients were evaluable for response and toxicity profiles. One patient achieved a complete response, and 11 patients achieved a partial response, with an overall response rate of 66.7% (95% CI, 45-89%). The main toxicity was hematological, a NCI grade 3-4 neutropenia in 16 patients (88.9%) during the treatment course. Febrile neutropenia occurred in three patients (16.6%). Grade 3 anemia occurred in eight patients (44.4%) and grade 3-4 thrombocytopenia occurred in 11 patients (61.1%). Non-hematological toxicity was mild and tolerable. No toxic death occurred. The median survival was 12.7 months and 1 year survival was 58.4%. The GIP combination chemotherapy produced a high response rate in advanced NSCLC; however, there was a relatively high percentage of hematological toxicity that still could be tolerated. A randomized trial comparing GIP to a two-drug combination of gemcitabine and cisplatin is planned.

AB - The aim of the present study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine, ifosfamide and cisplatin (GIP), administered every 3 weeks, in patients with inoperable non-small cell lung cancer (NSCLC). From October 1998 to July 1999, 18 previously untreated stages IIIb (4) and IV (14) patients were enrolled into the study. Gemcitabine and ifosfamide (with mesna as uroprotection) was administered on days 1 and 6, at a dose of 1000 and 1500 mg/m2, respectively; and cisplatin was given on day 1 at a dose of 60 mg/m2, every 3 weeks. All 18 patients were evaluable for response and toxicity profiles. One patient achieved a complete response, and 11 patients achieved a partial response, with an overall response rate of 66.7% (95% CI, 45-89%). The main toxicity was hematological, a NCI grade 3-4 neutropenia in 16 patients (88.9%) during the treatment course. Febrile neutropenia occurred in three patients (16.6%). Grade 3 anemia occurred in eight patients (44.4%) and grade 3-4 thrombocytopenia occurred in 11 patients (61.1%). Non-hematological toxicity was mild and tolerable. No toxic death occurred. The median survival was 12.7 months and 1 year survival was 58.4%. The GIP combination chemotherapy produced a high response rate in advanced NSCLC; however, there was a relatively high percentage of hematological toxicity that still could be tolerated. A randomized trial comparing GIP to a two-drug combination of gemcitabine and cisplatin is planned.

KW - Chemotherapy

KW - Cisplatin

KW - Gemcitabine

KW - Ifosfamide

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0034534993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034534993&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(00)00139-2

DO - 10.1016/S0169-5002(00)00139-2

M3 - Article

C2 - 11137205

AN - SCOPUS:0034534993

VL - 30

SP - 199

EP - 202

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -